TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16239860

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) plus parent training
Number of subjects: 61

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 61
Study: 11805685

Group type: EXPERIMENTAL
Intervention: 4PAD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bremer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PMT
Number of subjects: 10
Study: 10454704

Group type: EXPERIMENTAL
Intervention: Maintenance tocolysis
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Placebo or no maintenance treatment
Number of subjects: 1590
Study: 7561123

Group type: EXPERIMENTAL
Intervention: Genentech gp120(IIIB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MicroGeneSys gp160(IIIB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ImmunoAG gp160(IIIB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV‐1 uninfected gp120/gp160(IIIB) vaccinees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candidate HIV‐1 recombinant envelope subunit vaccines
Number of subjects: 0
Study: 2180792

Group type: EXPERIMENTAL
Intervention: cisapride 0.15 mg/kg intravenously
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: cisapride 0.2 mg/kg tid for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 396057

Group type: EXPERIMENTAL
Intervention: BCG vaccines
Number of subjects: 260000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260000
Study: 31574504

Group type: EXPERIMENTAL
Intervention: Intracorporeal side‐to‐side ileo‐colic laparoscopic anastomosis
Number of subjects: 416

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 416
Study: 31306043

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 85
Study: 28448655

Group type: EXPERIMENTAL
Intervention: Aflibercept, 2.0 mg
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Bevacizumab, 1.25 mg
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Ranibizumab, 0.3 mg
Number of subjects: 650

Group type: COMPARATOR
Intervention: Aflibercept vs Bevacizumab
Number of subjects: 650

Group type: COMPARATOR
Intervention: Ranibizumab vs Bevacizumab
Number of subjects: 650

Group type: COMPARATOR
Intervention: Aflibercept vs Ranibizumab
Number of subjects: 650

Group type: COMPARATOR
Intervention: All anti-VEGF treatments
Number of subjects: 650
Study: 26276455

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flat occlusal plane appliance (splint)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acupuncture and Flat occlusal plane appliance (splint)
Number of subjects: 40
Study: 24382705

Group type: EXPERIMENTAL
Intervention: Culturally Enhanced Video Feedback Engagement (CEVE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 19
Study: 26050277

Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip (PFT) tube
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard Mallinckrodt (Covidien) tube
Number of subjects: 58
Study: 19242384

Group type: EXPERIMENTAL
Intervention: Anger control training (ACT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 26
Study: 17524243

Group type: COMPARATOR
Intervention: SP (sulfadoxine-pyrimethamine)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: SP plus artesunate on day 0 (AS1)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: SP on day 0 and artesunate on each of days 0-2 (AS3)
Number of subjects: 600
Study: 15263880

Group type: EXPERIMENTAL
Intervention: 1 mg oral CDDZ + 2 mg midazolam by nasal route (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable (Group 2)
Number of subjects: 50
Study: 11171711

Group type: EXPERIMENTAL
Intervention: Salbutamol, 100 microg, two puffs qid for 10 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo inhalers, two puffs qid for 10 days
Number of subjects: 14
Study: 9766832

Group type: EXPERIMENTAL
Intervention: Lidocaine topical anesthetic
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 44
Study: 7850230

Group type: EXPERIMENTAL
Intervention: Rapid fluorescent methods for assessment of cholesterol and triglycerides, effective and total concentrations of albumin.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total albumin concentration measurement.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of cholesterol and triglycerides over the course of development of acute myocardial infarction.
Number of subjects: 0
Study: 2178853

Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline (400 mg sustained-release tablet)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous and oral pentoxifylline
Number of subjects: 16
Study: 840561

Group type: EXPERIMENTAL
Intervention: Formula 4 (3.0 gm/100 ml, 18:82)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Formula 1 (1.5 gm/100 ml, 60:40)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Formula 2 (3.0 gm/100 ml, 60:40)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Formula 3 (1.5 gm/100 ml, 18:82)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Pooled human milk
Number of subjects: 106
Study: 31132094

Group type: EXPERIMENTAL
Intervention: BEACOPP-14
Number of subjects: 5773

Group type: EXPERIMENTAL
Intervention: 6×BEACOPPesc
Number of subjects: 5773

Group type: EXPERIMENTAL
Intervention: 8×BEACOPPesc
Number of subjects: 5773

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 5773

Group type: EXPERIMENTAL
Intervention: Oral contraception during treatment
Number of subjects: 5773

Group type: EXPERIMENTAL
Intervention: Overall thrombotic events
Number of subjects: 5773

Group type: EXPERIMENTAL
Intervention: Advanced HL
Number of subjects: 5773

Group type: COMPARATOR
Intervention: Early-favorable HL
Number of subjects: 5773

Group type: COMPARATOR
Intervention: Early-unfavorable HL
Number of subjects: 5773
Study: 28968782

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine (DP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 0
Study: 26210387

Group type: EXPERIMENTAL
Intervention: SRP and PerioCol™CG (controlled-release device containing chlorhexidine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SRP and PerioCol™CG
Number of subjects: 40
Study: 23638466

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 858

Group type: COMPARATOR
Intervention: Glipizide titrated from 5 to 20 mg/day (mean dose 15 mg/day)
Number of subjects: 858
Study: 21859655

Group type: EXPERIMENTAL
Intervention: Micronutrients supplementation (n=97)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (n=99)
Number of subjects: 196
Study: 19255037

Group type: EXPERIMENTAL
Intervention: Preterm children
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Preterm children with brain injury
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Preterm children without brain injury
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Severe neonatal brain injury
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Antenatal steroids, higher maternal education, and 2-parent family
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Minority status
Number of subjects: 375

Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 375
Study: 17113008

Group type: EXPERIMENTAL
Intervention: Talc Poudrage (TP)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Talc Slurry (TS)
Number of subjects: 109
Study: 15488368

Group type: EXPERIMENTAL
Intervention: Exposure with decreased safety behaviors under cognitive rationale
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exposure with decreased safety behaviors under extinction rationale
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exposure with no change in safety behaviors
Number of subjects: 45
Study: 12928995

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 177

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 177
Study: 9933852

Group type: EXPERIMENTAL
Intervention: 400 U/kg of r‐HuEPO divided in 4 doses (100 U/kg each, every 4 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 200 U/kg of r‐HuEPO (50 U/kg each, every 4 days)
Number of subjects: 20
Study: 7755127

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2271079

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine cream (PVP-I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple-antibiotic ointment (Neosporin Ointment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 6775304

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin gel (15 to 30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral slow-release nitroglycerin compound (Lénitral) 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral slow-release nitroglycerin compound (Lénitral) 7.5 mg
Number of subjects: 0
Study: 12467334

Group type: EXPERIMENTAL
Intervention: Calcipotriene cream plus PUVA radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PUVA radiation alone
Number of subjects: 0
Study: 30876831

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks)
Number of subjects: 550
Study: 30342295

Group type: EXPERIMENTAL
Intervention: Cervical mobilisations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (motionless manual contact)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cervical mobilisations and Placebo
Number of subjects: 40
Study: 26591005

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 24630905

Group type: EXPERIMENTAL
Intervention: Educational program (2-day program with a half-day follow-up)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Self-study using a similar content handbook
Number of subjects: 188
Study: 22329789

Group type: EXPERIMENTAL
Intervention: 4-choice completion task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rapid serial visual presentation task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: binary confidence judgments
Number of subjects: 0
Study: 20816294

Group type: EXPERIMENTAL
Intervention: Schwarz appliance (expanded group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Schwarz appliance (nonexpanded group)
Number of subjects: 28
Study: 19088803

Group type: EXPERIMENTAL
Intervention: Enalaprilat (50 microg x min‐1 intracoronary infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20
Study: 16227145

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 5016

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5016
Study: 12105241

Group type: EXPERIMENTAL
Intervention: Persistent proteinuria (UP) >1.0 g/24 h at diagnosis
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 1-year level of 24-h UP
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Serum creatinine (SC) at 1 year
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: SC trends (slopes) over the prior year
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 154
Study: 10202242

Group type: EXPERIMENTAL
Intervention: Triple-dose (TD) gadolinium (Gd) enhanced MRI
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard-dose (SD) gadolinium (Gd) enhanced MRI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both Gd doses during clinical relapses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both Gd doses after clinical relapses
Number of subjects: 10
Study: 9304380

Group type: EXPERIMENTAL
Intervention: Glucose concentration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fructosamine (FA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin (HbA1)
Number of subjects: 21
Study: 2185495

Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression (IPC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High Voltage Pulsed Current (HVPC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo-HVPC
Number of subjects: 30
Study: 121483

Group type: EXPERIMENTAL
Intervention: Home IPPB therapy (at least 1 to 2 hours daily through a mouthpiece)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without IPPB therapy)
Number of subjects: 0
Study: 31050851

Group type: EXPERIMENTAL
Intervention: Exergame intervention (8 weeks, 3 sessions per week, 30 minutes each)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 51
Study: 28991063

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.625, 1.0, 1.5, 2.5, 4.0, or 6.25 mg)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.625, 1.0, 1.5, 2.5, 4.0, or 6.25 mg)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.625, 1.0, 1.5, 2.5, 4.0, or 6.25 mg)
Number of subjects: 270
Study: 24963079

Group type: EXPERIMENTAL
Intervention: Cognitive training group (N = 11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Computer games group (N = 11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist group (N = 10)
Number of subjects: 32
Study: 23804013

Group type: EXPERIMENTAL
Intervention: Expressive Writing
Number of subjects: 49

Group type: COMPARATOR
Intervention: Time Management (Control)
Number of subjects: 49
Study: 21610364

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (routine surgical procedures)
Number of subjects: 45
Study: 19309330

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 17108800

Group type: EXPERIMENTAL
Intervention: Dorsiflexor group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plantarflexor group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dorsi- and plantarflexor group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 12823153

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Omeprazole capsule 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Omeprazole MUPS tablet 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10630921

Group type: EXPERIMENTAL
Intervention: Citizen's Advice Bureau services
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 6
Study: 8777954

Group type: EXPERIMENTAL
Intervention: Inhaled heparin (1,000 U.kg‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 11
Study: 2070526

Group type: EXPERIMENTAL
Intervention: Bilateral tube insertion
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-treatment (control group)
Number of subjects: 43
Study: 6573318

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 grams as disodium salt, intramuscularly, every 12 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lignocaine (0.5% as diluent)
Number of subjects: 0
Study: 30696335

Group type: EXPERIMENTAL
Intervention: Walk program (8-month physical activity program)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 143
Study: 27824680

Group type: EXPERIMENTAL
Intervention: Azilsartan (20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg)
Number of subjects: 30
Study: 25278459

Group type: EXPERIMENTAL
Intervention: High progesterone (mid-luteal) phase with strong mental imagery
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low progesterone (follicular) phase with strong mental imagery
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Processing sensory features of images
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Processing conceptual characteristics of images
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 64
Study: 22961196

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) ointment
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 207
Study: 20798660

Group type: EXPERIMENTAL
Intervention: High-protein diet (PRO; 3 g protein·kg(‐1) body mass (BM)·d(‐1))
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normal diet (CON; 1.5 g protein·kg(‐1) BM·d(‐1))
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High-protein diet (PRO) during recovery training
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High-protein diet (PRO)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normal diet (CON)
Number of subjects: 2
Study: 19367171

Group type: EXPERIMENTAL
Intervention: Insulin glargine (two-thirds of the total daily insulin dose required) subcutaneous administration with 5% dextrose solution infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glucose-insulin-potassium (GIK) infusion (125 ml/h)
Number of subjects: 30
Study: 16688803

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg bid)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 15205242

Group type: EXPERIMENTAL
Intervention: Initial examination of astigmatism
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Longitudinal study of 108 children
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Presence of astigmatism
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Increased astigmatism
Number of subjects: 522
Study: 11309553

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg orally, 4 times with 12-hour intervals
Number of subjects: 16
Study: 9717038

Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) > or = 40
Number of subjects: 3395

Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) 30-40
Number of subjects: 3395

Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) 20-30
Number of subjects: 3395

Group type: COMPARATOR
Intervention: Cardiac Infarction Injury Score (CIIS) < 20
Number of subjects: 3395

Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) > or = 40 at 3 year follow-up
Number of subjects: 3395

Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) 30-40 at 3 year follow-up
Number of subjects: 3395

Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) 20-30 at 3 year follow-up
Number of subjects: 3395
Study: 7992068

Group type: EXPERIMENTAL
Intervention: Carboplatin/etoposide
Number of subjects: 265

Group type: COMPARATOR
Intervention: Cisplatin/etoposide
Number of subjects: 265
Study: 2568202

Group type: EXPERIMENTAL
Intervention: bromazepam 1.5 mg bidaily (B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: labetalol 100 mg bidaily (L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo bidaily (P1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo bidaily (P2)
Number of subjects: 20
Study: 31124504

Group type: EXPERIMENTAL
Intervention: Conventional laser treatment followed by additional posterior retinal laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional laser treatment (control group)
Number of subjects: 20
Study: 28891545

Group type: EXPERIMENTAL
Intervention: Protein C levels in SCA patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) levels in SCA patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Protein C levels in control group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antithrombin (AT) levels in control group
Number of subjects: 50
Study: 25065959

Group type: EXPERIMENTAL
Intervention: High-dose (HD) PLT prophylaxis
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Medium-dose (MD) PLT prophylaxis
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Low-dose (LD) PLT prophylaxis
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: All PLT transfusions
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Subsequent PLT transfusions
Number of subjects: 1102
Study: 23062105

Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Irrigation (PUI) with 0.04 taper
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sonic Irrigation (SI) with 0.04 taper
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Irrigation (PUI) with 0.08 taper
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sonic Irrigation (SI) with 0.08 taper
Number of subjects: 68
Study: 21996202

Group type: EXPERIMENTAL
Intervention: mTOR inhibitors with steroids
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (calcineurin inhibitor, mycophenolate mofetil or sodium plus steroids)
Number of subjects: 115
Study: 18488439

Group type: EXPERIMENTAL
Intervention: Active group (n = 40) participated in a 14-week rehabilitation program (3 h/week, 1.5 h of education and exercise and 1.5 h of cycling)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 40) reviewed routinely as medical outpatients
Number of subjects: 80
Study: 16508333

Group type: EXPERIMENTAL
Intervention: SLITone (1,000 STU per milliliter)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 10 IR solution
Number of subjects: 47

Group type: COMPARATOR
Intervention: 100 IR solution
Number of subjects: 47

Group type: COMPARATOR
Intervention: 300 IR solution
Number of subjects: 47
Study: 12495136

Group type: EXPERIMENTAL
Intervention: Experimental treatment (exact details not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (conventional group-sequential phase III designs)
Number of subjects: 0
Study: 10428734

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43